AID Targeting Engine Kiromic’s DIAMOND AI 2.0 target discovery engine enables accelerated identification of oncology targets, offering licensing or co-development deals with pharma/biotech seeking to speed candidate generation and reduce R&D risk.

Off-the-Shelf Platform With a multi-indication allogeneic gamma delta T-cell platform and ongoing development of off-the-shelf therapies such as ALEXIS-PRO-1 and ALEXIS-ISO-1, Kiromic presents partnering opportunities for firms seeking readily deployable immunotherapies, including co-development or asset licensing.

End-to-End Manufacturing Kiromic emphasizes end-to-end bioinformatics, AI targeting, and manufacturing technologies, suggesting a potential CMO-style partnership for other cell therapy programs, particularly gamma delta T-cell products, enabling joint development and supply for clinical trials.

Near-Term Assets Active IND filings for two cancer drug candidates indicate immediate collaboration opportunities in licensing, co-development, or strategic partnerships to advance these assets, with potential milestones and royalties.

US Market Access Located in Houston with a US-facing focus, Kiromic can partner with North American pharma, biotech, and contract research and manufacturing organizations to support trial execution, regulatory navigation, or regional manufacturing capacity for US-based studies.